Anti-inflammatory and anti-arthritic effects of new synthetic 3-(4-hydroxyphenyl)-4-(4-thiomethoxyphenyl)-1H-pyrrole-2,5-dione

Bioorganic and Medicinal Chemistry Letters

Volumn 22, Issue 6, 2012, Pages 2221-2225

  Shin, Ji Sun ^a   Noh, Young Su ^a   Yoo, Min Sang ^a   Lee, Jae Yeol ^a   Cho, Young Wuk ^a   Lee, Kyung Tae ^a  

^a Kyung Hee University   (South Korea)

Author keywords

3 (4 Hydroxyphenyl) 4 (4 thiomethoxyphenyl) 1H pyrrole 2,5 dione; Adjuvant arthritis; Cyclooxygenase 2; Cytokine

Indexed keywords

3(4 HYDROXYPHENYL) 4(4 THIOMETHOXYPHENYL) 1H PYRROLE 2,5 DIONE; ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; CYCLOOXYGENASE 2; IBUPROFEN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; MYELOPEROXIDASE; NITRIC OXIDE; PROSTAGLANDIN E2; UNCLASSIFIED DRUG;

ADJUVANT ARTHRITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; DRUG SCREENING; DRUG SYNTHESIS; ENZYME INHIBITION; INFLAMMATION; MACROPHAGE; NONHUMAN; PAW EDEMA; PROSTAGLANDIN BLOOD LEVEL; PROSTAGLANDIN RELEASE; RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, EXPERIMENTAL; CARRAGEENAN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; INFLAMMATION; INTERLEUKIN-1BETA; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MACROPHAGES; MALE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY;

RATTUS;

EID: 84862817116     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2012.01.100     Document Type: Article

References (23)

1. G. Sindhu, M. Ratheesh, G.L. Shyni, and A. Helen Immunopharmacol. Immunotoxicol. 31 2009 647
2. M. De Mattei, K. Varani, F.F. Masieri, A. Pellati, A. Ongaro, M. Fini, R. Cadossi, F. Vincenzi, P.A. Borea, and A. Caruso Osteoarthritis Cartilage 17 2009 252
3. J. Akaogi, T. Nozaki, M. Satoh, and H. Yamada Endocr. Metab. Immune. Disord. Drug Targets 6 2006 383
4. D. Yan, W. Han, Q. Bai, X. Zhao, X. Han, B. Du, and X. Zhu Lipids Health Dis. 10 2011 75
5. F. Berenbaum Joint Bone Spine 67 2000 561
6. C.D. Funk Science 2001 1871 294
7. I.G. Zarraga, and E.R. Schwarz J. Am. Coll. Cardiol. 49 2007 1
8. P. Rao, and E.E. Knaus J. Pharm. Pharmacol. Sci. 11 2008 81s
9. 2. The prostanoid product is quantified via EIA. As control inhibitors for COX-1 or COX-2, SC-560 (1 μM) or Dup-697 (100 nM) were used.
10. J.T. Moon, J.Y. Jeon, H.A. Park, Y.S. Noh, K.T. Lee, J. Kim, D.J. Choo, and J.Y. Lee Bioorg. Med. Chem. Lett. 20 2010 734
11. J.M. Cavaillon Biomed. Pharmacother. 48 1994 445
12. R. Mythilypriya, P.S. Sachdanandam, and P. Sachdanandam Chem. Biol. Interact. 179 2009 335
13. Y. Ma, X. Wang, X. Wu, X. Wei, L. Ma, H. Zheng, B. Qi, W. Zhu, Y. Luo, Y. Wei, and L. Chen Int. Immunopharmacol. 10 2010 1456
14. 12-18) 0.5 μg/μl. PCR analyses were performed on aliquots of the cDNA preparations to detect iNOS, IL-1β, IL-6, and β-actin (as an internal standard) gene expression using a thermal cycler (Perkin Elmer Cetus, CA, USA). Reactions were carried out in a volume of 25 μl containing; 1 unit of Taq DNA polymerase, 0.2 mM dNTP, ×10 reaction buffer, and 100 pmol of 5′ and 3′ primers. The PCR primers used in this study are listed below and were purchased from Bioneer (Seoul, Korea): sense strand iNOS, 5′-AAT GGC AAC ATC AGG TCG GCC ATC ACT-3′, anti-sense strand iNOS, 5′-GCT GTG TGT CAC AGA AGT CTC GAA CTC-3′; sense strand IL-1β, 5′-TGC AGA GTT CCC CAA CTG GTA CAT C-3′; anti-sense strand IL-1β, 5′-GTG CTG CCT AAT GTC CCC TTG AAT C-3′; sense strand IL-6, 5′-GAG GAT ACC ACT CCC AAC AGA CC-3′, anti-sense strand IL-6, 5′-AAG TGC-ATC ATC GTT GTT CAT ACA-3′; sense strand β-actin, 5′-TCA TGA AGT GTG ACG- TTG ACA TCC GT-3′, anti-sense strand β-actin, 5′-CCT AGA AGC ATT TGC GGT- GCA CGA TG-3′. After amplification, the PCR reactions were electrophoresised on 2% agarose gel and visualized by ethidium bromide staining and UV irradiation.
15. Z. Fan, B. Bau, H. Yang, and T. Aigner Cytokine 28 2004 17
16. N. Nishimoto, T. Kishimoto, and K. Yoshizaki Ann. Rheum. Dis. 59 Suppl 1 2000 i21
17. R.N. Maini, and P.C. Taylor Annu. Rev. Med. 51 2000 207
18. S.C. Ghivizzani, E.R. Lechman, R. Kang, C. Tio, J. Kolls, C.H. Evans, and P.D. Robbins Proc. Natl. Acad. Sci. U.S.A. 95 1998 4613
19. J. Rojas, M. Paya, I. Devesa, J.N. Dominguez, and M.L. Ferrandiz Naunyn-Schmiedeberg's Arch. Pharmacol. 368 2003 225
20. Cho, E. J.; An, H. J.; Shin, J. S.; Choi, H. E.; Ko, J.; Cho, Y. W.; Kim, H. M.; Choi, J. H.; Lee, K. T. J. Cell Biochem. 2011, 112, 3648. Western blotting: RAW 264.7 macrophages were collected by centrifugation and washed once with phosphate-buffered saline (PBS). The washed cell pellets were resuspended in extraction lysis buffer (50 mM HEPES pH 7.0, 250 mM NaCl, 5 mM EDTA, 0.1% Nonidet P-40, 1 mM PMSF, 0.5 mM DTT, 5 mM Na fluoride, and 0.5 mM Na orthovanadate) containing 5 μg/ml each of leupeptin and aprotinin and incubated with 20 min at 4 °C. Cell debris was removed by microcentrifugation, followed by quick freezing of the supernatants. The protein concentration was determined using the Bio-Rad protein assay reagent according to the manufacture's instruction. Cellular protein from treated and untreated cell extracts was electroblotted onto a PVDF membrane following separation on a 10-12% SDS-polyacrylamide gel electrophoresis. The immunoblot was incubated overnight with blocking solution (5% skim milk) at 4 °C, followed by incubation overnight with a primary antibody. Blots were washed four times with Tween 20/Tris-buffered saline (T/TBS) and incubated with a 1:1000 dilution of horseradish peroxidase-conjugated secondary antibody for 2 h at room temperature. Blots were again washed three times with T/TBS, and then developed by enhanced chemiluminescence (GE healthcare, WI, USA).
21. 12-18) 0.5 μg/μl. PCR amplification was performed using the incorporation of SYBR green. The oligonucleotide primers for IL-1β a designed from rat were AAA ATG CCT CGT GCT GTC TG (forward) and CCA CAG GGA TTT TGT CGT TG (reverse), for IL-6 a designed from rat were GCC ACT GCC TTC CCT ACT TC (forward) TGC CAT TGC ACA ACT CTT TTC (reverse) and the suitable size of synthesized cDNA were 137 and 160 bp, respectively. The results were expressed as the ratio of optimal density to GAPDH. Steady-state mRNA levels of IL-1β, IL-6, and GAPDH were determined by qPCR using the Takara thermal cycler dice® (Takara Bio Inc., Shiga, Japan).
22. D.T. Walz, M.J. DiMartino, and A. Misher J. Pharmacol. Exp. Ther. 178 1971 223
23. Stein, C.; Millan, M. J.; Herz, A. Pharmacol., Biochem. Behav. 1988, 31, 445. Adjuvant induced arthritis was elicited in Sprague-Dawley male rats weighing 180-200 g by intraplantar injection of Mycobacterium butyricum in Freund's complete adjuvant into the footpad (100 μl per rat). HMP (25 or 50 mg/kg, po) and ibuprofen (50 mg/kg, po) were first dissolved in vehicle solution (5% EtOH and 5% Tween 20 and diluted with saline) and orally administrated after 9 day of adjuvant injection for 11 days. Controls (CON) and vehicle were only administered with saline or vehicle solution after AIA induction. Paw volumes were measured at the beginning of the experiment by using a plethysmometer for 19 days. Moreover, arthritis was assessed every third day by the clinical index of the infected paw. The arthritis index was determined by the degree of the inflammation, 0 = normal; 1 = erythema of toes; 2 = erythema and swelling of paws; 3 = swelling of ankles; 4 = complete swelling of whole leg and inability to bend it. Arthritis index for each rat was calculated by adding the four scores of individual paws.